Mayne Pharma Pursues ‘Aggressive Rationalization’ To Rally Revenue

Mayne Winds Up Unprofitable Generics In A Bid For Efficiency And Focus

 
• By Rosalind Rei
  
Businessman financial charts reports
Mayne has pruned its generics portfolio of unprofitable products • Source: Shutterstock

More from Strategy

More from Business